Despite the potential benefit of primaquine in reducing Plasmodium falciparum transmission
and radical cure of Plasmodium vivax and Plasmodium ovale infections, concerns over risk …

Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is the most common
enzymopathy globally, and deficient individuals may experience severe hemolysis following …

Background The distribution of the enzymopathy glucose-6-phosphate dehydrogenase
(G6PD) deficiency is linked to areas of high malaria endemicity due to its association with …

Primaquine and other 8-amnoquinoline based anti-malarials can cause haemolysis in
subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Correct diagnosis of …

Background Primaquine is recommended by the World Health Organization (WHO) for
radical treatment of Plasmodium vivax malaria. This drug is known to provoke acute …

Background Malaria transmission-blocking anti-malarial drugs, such as primaquine, offers
an effective strategy for reducing the incidence of falciparum malaria. However, this drug …

Background User-friendly, accurate, point-of-care rapid tests to detect glucose-6-phosphate
dehydrogenase deficiency (G6PDd) are urgently needed at peripheral level to safely …

Abstract Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most
common enzymopathy worldwide. Primaquine is the only licensed drug that effectively …

Background WHO recommends gametocytocidal, single low-dose primaquine for blocking
the transmission of Plasmodium falciparum; however, safety concerns have hampered the …

Development of reliable, easy-to-use, rapid diagnostic tests (RDTs) to detect glucose-6-
phosphate dehydrogenase (G6PD) deficiency at point of care is essential to deploying …